(All fields required)
Please enter a valid email.
Please enter your name.
Andrew D. Hershey, MD, PhD, FAHS Director, Division of Neurology
is interested in the characterization, molecular pathophysiology and neurophysiological, and outcome of pediatric and adolescent headache. This has extended from characterization of headache and changes across the ages and for specific headache and migraine types. The pathophysiology has included gene expression patterns of risk and response, mitochondrial cofactors and neurophysiological responses.
Director, Division of Neurology
Professor, UC Department of Pediatrics
Headaches; migraines; neurogenetics; neurometabolic disorders
Andrew Hershey, MD, PhD, FAHS, received his undergraduate degree at the University of Iowa, Iowa City, Iowa. He earned an honors degree in biochemistry; his research involved the enzyme kinetic properties of alcohol dehydrogenase in yeast.
After undergraduate school, Dr. Hershey attended the MD/PhD program at Washington University, St. Louis, Missouri. His PhD research thesis was entitled: "The Rat Substance P Receptor: cDNA and Genomic Cloning, Functional Expression, mRNA Distribution, and Mutational Analysis of Desensitization Responses."
After earning his MD and PhD, Dr. Hershey was an intern and resident in pediatrics at St. Louis Children's Hospital, St. Louis, MO. He then was an adult neurology resident at Barnes-Jewish Hospital, St. Louis, MO, followed by his child neurology fellowship at St. Louis Children's Hospital, St. Louis, MO.
After his fellowship, Dr. Hershey joined the faculty at Cincinnati Children's Hospital Medical Center, Ohio, where he is director of the Headache Center.
Dr. Hershey's research interests currently include the improved diagnosis and treatment of childhood headache disorders, characterization of outcome responses, studies in new pharmacological and non-pharmacological treatment regimes, and the neurogenetics of migraines.
Hershey AD, Burdine D, Kabbouche MA, Powers SW. Genomic expression patterns in medication overuse headaches. Cephalalgia. 2011 Jan;31(2):161-71.
O'Brien HL, Kabbouche MA, Hershey AD. Treatment of acute migraine in the pediatric population. Curr Treat Options Neurol. 2010 May;12(3):178-85.
Hershey AD, Kabbouche MA, Powers SW. Treatment of pediatric and adolescent migraine. Pediatr Ann. 2010 Jul;39(7):416-23. Review.
Wang X, Xiang J, Wang Y, Pardos M, Meng L, Huo X, Korostenskaja M, Powers SW, Kabbouche MA, Hershey AD. Identification of abnormal neuromagnetic signatures in the motor cortex of adolescent migraine. Headache. 2010 Jun;50(6):1005-16.
Hershey AD. Recent developments in pediatric headache. Curr Opin Neurol. 2010 Jun;23(3):249-53. Review.
Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010 Feb;9(2):190-204. Review.
Slater S, Crawford MJ, Kabbouche MA, LeCates SL, Cherney S, Vaughan P, Segers A, Manning P, Burdine D, Powers SS, Hershey AD. Effects of gender and age on paediatric headache. Cephalalgia. 2009 Sep;29(9):969-73.
Khatri R, Hershey AD, Wong B. Prochlorperazine -- treatment for acute confusional migraine. Headache. 2009 Mar;49(3):477-80.Hershey AD. Menstrual migraine: how early can it start? Headache. 2009 Mar;49(3):348-9. Crawford MJ, Lehman L, Slater S, Kabbouche MA, LeCates SL, Segers A, Manning P, Powers SW, Hershey AD. Menstrual migraine in adolescents. Headache. 2009 Mar;49(3):341-7.
Todd M. Arthur, MD Child Neurologist, Division of Neurology
is interested in mild traumatic brain injuries (concussions) in children. It is hoped by approaching the diagnosis and treatment of concussion in a systematic manner that we can improve the quality of life and outcomes of children following mild traumatic brain injuries.
Child Neurologist, Division of Neurology
Assistant Professor, UC Department of Pediatrics
MD: University of Cincinnati College of Medicine, Cincinnati, OH.
Residency: Pediatrics, West Virginia University, Charleston; Pediatric Neurology, University of Washington.
Fellowship: Pediatric Clinical Neurophysiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: American Board of Pediatrics, 2002.
Anna Weber Byars, PhD, ABPP-Cn Pediatric Neuropsychologist, Division of Neurology
is focused on neuropsychological and behavioral aspects of epilepsy. She also collaborates with researchers in the Imaging Research Center on studies of cognitive development as well as clinicians conducting clinical trials in genetic diseases.
Pediatric Neuropsychologist, Division of Neurology
Associate Professor, UC Department of Pediatrics
Functional MRI; stroke; epilepsy; language disorders
PhD: University of Alabama at Birmingham, Birmingham, AL.
Internship: West Virginia University School of Medicine, Morgantown, WV.
Fellowship: Pediatric Neuropsychology, Children's Hospital Medical Center, Cincinnati, OH.
Jamie K. Capal, MD Pediatric Neurologist, Division of Neurology
has research interests focusing on children with autism spectrum disorders and related neurodevelopmental conditions. Current research projects include understanding the cognitive, behavioral, and language aspects of children with autism spectrum disorders and abnormal EEG but without concurrent clinical seizures. She is also involved in the Tuberous Sclerosis Clinic at Cincinnati Children’s Hospital Medical Center and related research projects.
Pediatric Neurologist, Division of Neurology
Child neurology; developmental pediatrics; autism; tuberous sclerosis
Dr. Capal’s clinical and research interests focus on children with autism spectrum disorders and related neurodevelopmental conditions. Current research projects include understanding the cognitive, behavioral, and language aspects of children with autism spectrum disorders and abnormal EEG but not always with concurrent clinical seizures. A natural extension of my research has led to interest in tuberous sclerosis complex (TSC), where autism, abnormal EEG, and seizures are frequent and interdependent. The genetic and molecular basis of TSC is well established, which provides an ideal platform for further investigation into the underlying mechanisms responsible and, in turn, discover new molecular-based targeted therapies. The TSC Clinic at Cincinnati Children’s Hospital Medical Center is the largest of its kind in the world, providing comprehensive, multidisciplinary clinical care to TSC patients of any age. This work led efforts that resulted in the first ever FDA-approved medical therapy for TSC in 2010 using the mTOR inhibitor everolimus. Our long-term goal is to refine and apply these and next-generation therapies for patients with TSC.
BA: Biology with Honors, Ithaca College, Ithaca, NY, 2002.
MD: Albany Medical College, Albany, NY, 2002.
Internship: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2006-2007.
Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.
Resident/Fellow: Pediatric Neurodevelopmental Disabilities, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008-1012.
James (Jim) J. Collins, MD, PhD
Congenital muscular dystrophies; merosin-deficient congenital muscular dystrophy
Collins J and Bönneman CG. Congenital Muscular Dystrophies: Toward Molecular Therapeutic Intervention. Current Neurology and Neuroscience Reports. 2010 Mar;10(2):83-91.
Collins J, Tang LY, Dimmock D, Morehart P, Bove K, Wong LJC, Wong B. Progressive myofiber changes of a childhood mitochondrial DNA depletion syndrome with a novel Thymidine Kinase 2 gene mutation. Neuromuscul Disord. 2009;19:784-787.
Allen D. DeSena, MD, MPH Pediatric Neurologist, Division of Neurology
does clinical research as it pertains to the emerging field of pediatric neuroimmunology. He has interest in determining best practices for patients in the acute and subacute period for neuroimmunologic conditions. He also has interest in endeavors to better manage pediatric patients with MS, NMO, transverse myelitis, and autoimmune encephalitis, such as anti-NMDA receptor antibody encephalitis.
Assistant Professor, UC Department of Neurology
Multiple sclerosis, transverse myelitis, neuromyelitis optica, autoimmune encephalitis, anti-NMDA receptor antibody encephalitis, opsoclonus-myoclonus syndrome, antibody-mediated central nervous system disorders.
MD: Loyola-Stritch School of Medicine, Maywood, IL, 2006.
Residency: General Pediatrics, Tulane-Ochsner General Pediatrics Residency, New Orleans, LA, 2006-2009.
Residency: Child Neurology Residency, UT Southwestern Medical Center, Dallas, TX, 2009-2012.
Fellowship: Pediatric and Adult Neuroimmunology Fellowship, UT Southwestern Medical Center, 2012-2014.
Certification: General Pediatrics, 2009; Neurology with special qualifications in Child Neurology, 2012.
DeSena AD, Greenberg BM, Graves D. "Light switch" mental status changes and irritable insomnia are two particularly salient features of anti-NMDA receptor antibody encephalitis. Pediatr Neurol. 2014 Jul;51(1):151-3.
DeSena AD, Greenberg BM, Graves D. Three Phenotypes of Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis in Children: Prevalence of Symptoms and Prognosis. Pediatr Neurol. 2014 May 29.
DeSena A, Graves D, Morriss MC, Greenberg BM. Transverse myelitis plus syndrome and acute disseminated encephalomyelitis plus syndrome: a case series of 5 children. JAMA Neurol. 2014 May;71(5):624-9.
Desena A, Graves D, Warnack W, Greenberg BM. Herpes simplex encephalitis as a potential cause of anti-N-methyl-D-aspartate receptor antibody encephalitis: report of 2 cases. JAMA Neurol. 2014 Mar;71(3):344-6.
David Neal Franz, MD Founding Director, Tuberous Sclerosis Clinic
focuses on using a combination of clinical investigation, basic science research and innovative social programs to improve clinical care for patients with tuberous sclerosis complex (TSC). He and his team are active in human clinical trials with mTOR inhibitors to treat subependymal giant cell astrocytoma (SEGA), epilepsy and cognitive disabilities that occur in patients with TSC. In the laboratory, he is focused on understanding the mechanisms through which mTOR dysregulation in the brain contributes to TSC disease pathogenesis and developing suitable biomarkers capable of predicting disease severity and treatment response.
Founding Director, Tuberous Sclerosis Clinic
Associate Director of Clinical Affairs, Division of Neurology
Tuberous sclerosis (adults and children); neuropharmacology; neurocutaneous disorders; general pediatric neurology
David Neal Franz, MD, was born and raised in Dayton, Ohio. He received his undergraduate degree in history and literature from Earlham College in Richmond, Indiana.
After completing his training, he served as assistant professor of neurology and pediatrics at Wright State University before returning to Cincinnati Children's Hospital Medical Center.
He established the Cincinnati Tuberous Sclerosis Clinic in 1993, to assist in the medical care of patients who have or are suspected of having tuberous sclerosis. The purpose of the clinic is not to replace care from the child's pediatrician or family physician, but to assist the primary care physician in dealing with those aspects unique to tuberous sclerosis that affect the child's health or development. The basis of the clinic is the realization that people with tuberous sclerosis are different from other individuals who have epilepsy, learning disabilities, behavior problems, etc.
For too long, the unique problems found in this disease have been lumped together with similar disorders, despite the fact that research has shown that disorders of the brain, heart, kidney, and other organs in tuberous sclerosis are quite different.
Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics. 2010 Oct;41(5):199-208.
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11.
Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010 Sep;138(3):674-81.
Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926-33.
Schmithorst VJ, Altes TA, Young LR, Franz DN, Bissler JJ, McCormack FX, Dardzinski BJ, Brody AS. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis. AJR Am J Roentgenol. 2009 Apr;192(4):1037-44.
Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10(5):299-313. Review.
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008 Jan 10;358(2):140-51.
Levine NB, Collins J, Franz DN, Crone KR. Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim Invasive Neurosurg. 2006 Oct;49(5):317-20.
Collins JJ, Tudor C, Leonard JM, Chuck G, Franz DN. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006 Jan;21(1):53-7.
Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006 Mar;59(3):490-8.
Donald L. Gilbert, MD, MS Director, Movement Disorder Clinic and Tourette's Syndrome Clinic
Director, Movement Disorder Clinic and Tourette's Syndrome Clinic
Movement disorders; Tourette's syndrome; Sydenham's chorea; kernicterus; dystonia; ataxia; clinical research; transcranial magnetic stimulation
Donald Gilbert, MD, earned his Bachelor of Arts at Princeton University, where he majored in philosophy. He subsequently earned his MD at the University of Michigan and spent a year at the National Institutes of Health as a Howard Hughes Medical Institute Research Scholar. Dr. Gilbert did his pediatrics and neurology training at John Hopkins in Baltimore and is board certified in neurology with special competence in child neurology. Dr. Gilbert has an MS in clinical research design and statistical analysis from the University of Michigan.
At Cincinnati Children's, Dr. Gilbert directs the Movement Disorders and Tourette's Syndrome Clinics, which specialize in evaluation and pharmacologic treatment of tics, chorea, tremor, dystonia, stereotypies, ataxia, and other movement disorders. Dr. Gilbert directs or participates in a number of single and multi-center studies into causes and treatments of Tourette's Syndrome. Dr. Gilbert directs the Transcranial Magnetic Stimulation Laboratory at Cincinnati Children's.
Hong YH, Wu SW, Pedapati EV, Horn PS, Huddleston DA, Laue CS, Gilbert DL. Safety and Tolerability of Theta Burst Stimulation versus Single and Paired Pulse Transcranial Magnetic Stimulation: A Comparative Study of 164 Pediatric Subjects. Frontiers in Neuroscience. 2015. doi: 10.3389/fnhum.2015.00029
Dietrich A, Fernandez TV, King RA, State MW, Tischfield JA, Hoekstra PJ, Heiman GA, and the TIC Genetics Collaborative Group. The Tourette International Collaborative Genetics (TIC Genetics) study, finding the genes causing Tourette Syndrome: objectives and methods. Eur Child Adolesc Psychiatry, 2014. DOI 10.1007/s00787-014-0543-x
Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 Receptor Antagonist, Ecopipam, for treatment of tics in Tourette Syndrome. Clinical Neuropharmacology, 2014. 37:26-30.
Chen TH, Wu SW, Dixon S, Shahana N, Huddleston DA, Sarvis AR, Sallee FR, Gilbert DL. Motor Cortex Physiology and Stop Signal Reaction Times as Predictors and Correlates of Atomoxetine Responses in Children with ADHD. Journal of Child Neurology, 2014. 29:1672-9. DOI: 10.1177/0883073813513333.
Wu SW, Maloney T, Gilbert DL, Dixon SG, Horn PS, Huddleston DA, Eaton K, Vannest J. Functional MRI-navigated Repetitive Transcranial Magnetic Stimulation of Supplementary Motor Area in Chronic Tic Disorders. Brain Stimulation. 2014. 7: 212-218.
Gilbert DL, Patterson MC, Pugh JA, Ridel KR, Reynolds TQ, Valencia I. Views of Recently First-Certified US Child Neurologists on Their Residency Training. Journal of Child Neurology, 2013. 28 (3): 332-339. doi 10.1177/0883073812473644.
Wu SW, Shahana N, Huddleston DA, Gilbert DL. Effects of 30 Hz Theta Burst Transcranial Magnetic Stimulation on the primary motor cortex. Journal of Neuroscience Methods, 2012; 208: 161-164.
Wu SW, Gilbert DL, Shahan N, Huddleston DA, Mostofsky SH. Transcranial Magnetic Stimulation Measures in Attention Deficit/Hyperactivity Disorder. Pediatric Neurology, 2012; 47: 177-185. Doi: 10.1016/j.pediatricneurol.2012.06.0003.
Wu SW, Shahana N, Huddleston DA, Lewis AN, Gilbert DL. Safety and Tolerability of Theta Burst Stimulation in Children. Developmental Medicine and Child Neurology. 2012, 54 (7): 636-639. Doi: 10.111/j.1469-8749.2012.04300.x.
Edden RAE, Crocetti D, Zhu H, Gilbert DL, Mostofsky SH. Reduced GABA concentration in Attention Deficit/Hyperactivity Disorder. Archives of General Psychiatry. 2012; 69: 750-753. PMID: 22752239.
Tracy A. Glauser, MD Associate Director, Cincinnati Children's Research Foundation
Associate Director, Cincinnati Children's Research Foundation
Director, Comprehensive Epilepsy Center
Co-Director, Genetic Pharmacology Service
Epilepsy; pharmacogenetics; clinical pharmacology
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2010 Nov 18. doi: 10.1111/j.1528-1167.2010.02789.x.
Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010 May;18(1-2):94-9
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.
Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.
Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.
Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6.
Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009 Sep 1;73(9):658-64.
Glauser TA, Sankar R; Co-chairs of the Leadership in Epilepsy, Advocacy, and Development Faculty. Core elements of epilepsy diagnosis and management: expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty. Curr Med Res Opin. 2008 Dec;24(12):3463-77.
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.
Christina Gross, PhD
studies the molecular mechanisms underlying Fragile X syndrome and other autism spectrum and epilepsy disorders. In particular, the lab is interested in neuron-specific regulation of the PI3K pathway, and in the translational regulation of potassium channels crucial for neuronal excitability. The goal is to understand how defects in these mechanisms lead to neuronal diseases, and may serve as therapeutic targets.
Visit the Gross Lab.
Molecular neuroscience, fragile X syndrome
Visit the Gross Lab.
Diploma in Biochemistry: Ruhr University Bochum, Germany, 2000.
PhD: Free University of Berlin, Germany, 2004.
Sasaki Y, Gross C, Xing L, Goshima Y, Bassell GJ. Identification of axon-enriched microRNAs localized in growth cones of cortical neurons. Dev Neurobiol. 2014 Mar;74(3):397-406.
Gross C, Bassell GJ. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. Front Mol Neurosci. 2014 Feb 13;7:12.
Gross C, Bassell GJ. Excess Protein Synthesis in FXS Patient Lymphoblastoid Cells Can Be Rescued with a p110beta-Selective Inhibitor. Mol Med. 2012 May 9;18:336-45.
Gross C, Berry-Kravis EM, Bassell GJ. Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond. Neuropsychopharmacology. 2012 Jan;37(1):178-95.
Swanger SA, Bassell GJ, Gross C. High-Resolution Fluorescence In Situ Hybridization to Detect mRNAs in Neuronal Compartments In Vitro and In Vivo. Methods Mol Biol. 2011;714:103-123.
Jakkamsetti V, Tsai N-P, Gross C, Molinaro G, Collins KA, Nicoletti F, Wang KH, Osten P, Bassell GJ, Gibson JR, Huber KM. Experience-Induced Arc/Arg3.1 Primes CA1 Pyramidal Neurons for Metabotropic Glutamate Receptor-Dependent Long-Term Synaptic Depression. Neuron. 2013 Oct 2;80(1):72-9.
Pak C, Garshasbi M, Kahrizi K, Gross C, Apponi LH, Noto JJ, Kelly SM, Leung SW, Tzschach A, Behjati F, Abedini SS, Mohseni M, Jensen LR, Hu H, Huang B, Stahley SN, Liu G, Williams KR, Burdick S, Feng Y, Sanyal S, Bassell GJ, Ropers HH, Najmabadi H, Corbett AH, Moberg K, Kuss AW. Mutation of a Conserved Polyadenosine RNA binding Protein, ZC3H14/dNab2, Impairs Neural Function in Drosophila and Humans. Proc Natl Acad Sci USA. 2011 Jul 26;108(30):12390-5.
Muddashetty RS, Nalavadi VC, Gross C, Yao X, Xing L, Laur O, Warren ST, Bassell GJ. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation and mGluR signaling. Mol Cell. 2011 Jun 10;42(5):673-88.
Gross C, Yao X, Pong DL, Jeromin A, Bassell GJ. Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. J Neurosci. 2011 Apr 13;31(15):5693-8.
Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci. 2010 Aug 11;30(32):10624-38.
Barbara E. Hallinan, MD, PhD Pediatric Neurologist, Division of Neurology
focuses on investigating the neurochemical mechanisms responsible for the onset of epilepsy in infants, especially infantile spasms. Early diagnosis and treatment of epilepsy in this age group has the potential to improve developmental outcome. It is hoped that a better understanding of the pathogenesis of epilepsy in infants will shift the treatment paradigm from managing the clinical convulsions to correcting the underlying neurochemical pathology.
Dent CL, Spaeth JP, Jones BV, Schwartz SM, Glauser TA, Hallinan B, Pearl JM, Khoury PR, Kurth CD. Brain magnetic resonance imaging abnormalities after the Norwood procedure using regional cerebral perfusion. J Thorac Cardiovasc Surg. 2006 Jan;131(1):190-7. Retraction in: J Thorac Cardiovasc Surg. 2006 Jun;131(6):1226.
Dent CL, Spaeth JP, Jones BV, Schwartz SM, Glauser TA, Hallinan B, Pearl JM, Khoury PR, Kurth CD. Brain magnetic resonance imaging abnormalities after the Norwood procedure using regional cerebral perfusion. J Thorac Cardiovasc Surg. 2005 Dec;130(6):1523-30.
Katherine D. Holland, MD, PhD Pediatric Epileptologist, Division of Neurology
focuses on understanding the reasons medications fail to control seizures in certain people with epilepsy. This work includes development of clear definitions of drug response, analysis of genetic factors that predict treatment response and analyzing the neurophysiological differences between treatment responsive and treatment resistant epilepsy. The goal of this work is to predict treatment response so that care can be more individualized.
Pediatric Epileptologist, Division of Neurology
Mechanisms of epileptogenesis
Paul S. Horn, PhD
is a statistician who is part of the Division of Neurology. He works on various research projects including the data analysis of epilepsy and seizures, neuromuscular conditions, mitochondrial diseases, and migraines. His other statistical interests include robust and nonparametric methods and their application to the derivation of reference ranges.
Robustness; nonparametrics; statistical computing; simulations; reference intervals.
Hershey AD, Horn PS, Kabbouche MA, O’Brien HL, Powers SW. Genomic expression patterns in menstrually-related migraine in adolescents. Headache: The Journal of Head and Face Pain. 2012; 52(1): 68-79.
Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Sagers A, Manning P, Powers SW, Hershey AD. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011; 31(8): 897-905.
Seo JH, Holland K, Rose D, Rozhkov L, Fujiwara H, Byars A, Arthur T, DeGrauw T, Leach JL, Gelfand MJ, Miles L, Mangano FT, Horn P, Lee KH. Multimodality imaging in the surgical treatment of children with non-lesional epilepsy. Neurology. 2011; 76(1): 41-48.
Pesce A, West C, Rosenthal M, West R, Crews B, Mikel C, Almazan P, Latyshev S, Horn PS. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician. 2010;13(3): 283-287.
Sherman KE, Shire NJ, Rouster SD, Peters MG, Koziel MJ, Chung RT, Horn PS. Viral kinetics in hepatitis C or hepatitis C/humin immunodeficiency virus-infected patients. Gastroenterology. 2005;128(2): 313-327.
Horn PS, Wolfe DA. A rank-based goodness-of-fit approach to testing for non-additivity in the two-way layout with no replications. Computational Statistics and Data Analysis. 2004; 46(2): 357-376.
Horn PS, Feng L, Li YM, Pesce AJ. The effect of outliers and non-healthy individuals on reference interval determination. Clinical Chemistry. 2001; 47(12): 2137-2145.
Horn PS, Pesce AJ, Copeland B. A robust approach to reference interval estimation and evaluation. Clinical Chemistry. 1998; 44(3): 622-631.
Horn PS. Robust quantile estimators for skewed populations. Biometrika. 1990; 77(3): 631-636.
Horn PS. A biweight prediction interval for random samples. Journal of the American Statistical Association. 1988; 83(1) : 249-256.
Sejal V. Jain, MD Director, Epilepsy-Sleep Clinical Program
is interested in the field of sleep and epilepsy and their interactions. Working on identifying prevalence of sleep disorder, screening methods and ideal treatments for sleep disorders in patients with epilepsy. The goal is also to identify the impact of treatment of sleep disorders on seizure control in these patients.
Director, Epilepsy-Sleep Clinical Program
Director, Epilepsy/Clinical Neurophysiology Fellowship Program
Medical and surgical management of epilepsy; sleep disorders
Dr. Jain is a clinical researcher who is trained in pediatric epilepsy and sleep medicine. Her clinical research is focused on sleep disorders in children with epilepsy. The core of her research is to identify the best treatment options for sleep disorders in children with epilepsy and evaluate the impact on seizure control. Dr. Jain is also interested in antiepileptic drug trials.
Dr. Jain developed and is currently directing the Epilepsy-Sleep Clinical Program. She also directs the Epilepsy/Clinical Neurophysiology Fellowship Program. She is ranked among America’s top physicians (Consumer Research Council of America, 2009-2012).
Jain SV, Simakajornboon N, Arthur TM. Central sleep apnea: does stabilizing sleep improve it? J Child Neurol. 2014 Jan;29(1):96-8.
Jain SV, Simakajornboon N, Glauser, TA. Provider practices impact adequate diagnosis of sleep disorders in children with epilepsy. J Child Neurol. 2013 May;28(5):589-95.
Natarajan, N, Jain SV, Chaudhry H, Hallinan BE, Simakajornboon N. Narcolepsy-cataplexy: is streptococcal infection a trigger? J Clin Sleep Med. 2013 Mar 15;9(3):269-70.
Jain SV, Horn PS, Simakajornboon N, Glauser, TA. Obstructive sleep apnea and primary snoring in children with epilepsy. J Child Neurol. 2013 Jan;28(1):77-82.
Fujiwara H, Greiner HM, Hemasilpin N, Lee KH, Holland-Bouley K, Arthur T, Morita D, Jain SV, Mangano FT, Degrauw T, Rose DF. Ictal MEG onset source localization compared to intracranial EEG and outcome: improved epilepsy presurgical evaluation in pediatrics. Epilepsy Res. 2012 May;99(3):214-24.
Jain SV, Simakajornboon S, Shapiro SM, Morton LD, Leszczyszyn DJ, Simakajornboon N. Obstructive sleep apnea in children with epilepsy: prospective pilot trial. Acta Neurol Scand. 2012 Jan;125(1):e3-6.
Jain SV, Kothare SV. Should we be targeting the sleep-wake patterns of children with epilepsy? Neuropsychiatry. 2011;1(6), 517–520.
Jain SV. Sleep Terrors and Confusional Arousals in Children and Adolescent. In Kothare SV and Ivanenko A. Prasomnia: Clinical Characteristics and Treatment. Springer. 2013.
Arya R, Jain SV. Sleep Walking in Children and Adolescent. In Kothare SV and Ivanenko A. Prasomnia: Clinical Characteristics and Treatment. Springer. 2013.
Jain SV, Morton LD. Evaluating the Child with Seizure: In Pellock JM, Dodson EW, Bourgeois BF, and Nordlii DR: Pediatric Epilepsy, Diagnosis and Treatment. New York, Demos Medical Publishing: Nov 2007.
Marielle A. Kabbouche, MD Child Neurologist, Division of Neurology
is interested in acute treatment of intractable migraine headache including emergency room evaluation and treatment as well as inpatient therapies. The goal is not only to identify intractable headache but being able to identify short-term as well as long-term outcome to these interventions in children and adolescents.
Headaches; migraines; acute and inpatient treatment of intractable headache
Hershey AD, Kabbouche MA, Powers SW. Treatment of pediatric and adolescent migraine. Pediatr Ann. 2010 Jul;39(7):416-23.
Kabbouche MA, Cleves C. Evaluation and management of children and adolescents presenting with an acute setting. Semin Pediatr Neurol. 2010 Jun;17(2):105-8.
Kabbouche MA, Powers SW, Segers A, LeCates S, Manning P, Biederman S, Vaughan P, Burdine D, Hershey AD. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009 Jan;49(1):106-9.
Kabbouche MA, Gilman DK. Management of migraine in adolescents. Neuropsychiatr Dis Treat. 2008 Jun;4(3):535-48. Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Curr Pain Headache Rep. 2005 Oct;9(5):363-7. Kabbouche MA, Linder SL. Acute treatment of pediatric headache in the emergency department and inpatient settings. Pediatr Ann. 2005 Jun;34(6):466-71. Kabbouche MA, Powers SW, Vockell ALB, LeCates SL, Ellinor PL, Segers A, Manning P, Hershey AD. Outcome of a multidisciplinary approach of pediatric migraine at 1, 2, and 5 years. Headache. 2005;45:1298-1303.
Kabbouche MA. Migraine variants. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009.
Kabbouche MA. Other primary headaches. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009. Kabbouche MA. Emergent therapy for children and adolescent. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009.
Darren S. Kadis, PhD
studies brain-behavior relationships using modern neuroimaging techniques (i.e., MRI, MEG, etc.). His research is directed at understanding the typical organization of the brain, the role of early experience on brain structure and functional representation, and the vulnerability and plasticity of the brain in the context of early neurological insult.
Neuroimaging; epilepsy; language
Dr. Kadis received his PhD through the Department of Psychology at the University of Toronto, with a distinction in Neuroscience and training in clinical neuropsychology. He conducted his graduate and post-doctoral research at the Hospital for Sick Children in Toronto, gaining experience with invasive (i.e., intracarotid sodium amobarbital procedure, electrocortical stimulation mapping) and newer noninvasive (e.g., fMRI, MEG) brain mapping procedures. His research is directed at understanding the typical organization of the brain, the role of early experience on brain structure and functional representation, and the vulnerability and plasticity of the brain in the context of early neurological insult. Currently, Dr. Kadis uses MEG in concert with structural neuroimaging and neuropsychological procedures to study speech and language representation and plasticity in the brains of children.
Elliott IM, Kadis DS, Lach LM, Olds J, McCleary L, Whiting S, Snyder T, Smith ML. Quality of life in young adults who underwent respective surgery for epilepsy in childhood. Epilepsia. 2012;53(9):1577-1586.
Kadis DS, Pang EW, Mills T, Taylor MJ, McAndrews MP, Smith ML. Characterizing the normal developmental trajectory of expressive language lateralization using magnetoencephalography. Journal of the International Neuropsychological Society. 2011;17(5):896-904.
Pang EW, Wang F, Malone M, Kadis DS, Donner EJ. Localization of Broca’s area using verb generation tasks in MEG: Validation against fMRI. Neuroscience Letters. 2011;490:215-219.
Smith ML, Kelly K, Kadis DS, Elliott I, Olds J, Whiting S, Snyder T. Self-reported symptoms of psychological well-being in young adults who underwent resective epilepsy surgery in childhood. Epilepsia. 2011:52(5):891-899.
Kadis DS, Kerr EN, Rutka JT, Snead III OC, Weiss SK, Smith ML. Pathology type does not predict language lateralization in children with medically intractable epilepsy. Epilepsia. 2009;50(6):1498-1504.
Kadis DS, Smith ML, Mills T, Pang EW. MEG localization of expressive language cortex in healthy children: Application to paediatric clinical populations. Down Syndrome Quarterly. 2008;10(2):5-12.
Elliott IM, Lach L, Kadis DS, Smith ML. Psychosocial outcomes in children two years after epilepsy surgery: Has anything changed? Epilepsia. 2008;49(4):634-641.
Kadis DS, Iida K, Kerr EN, Logan WJ, McAndrews MP, Ochi A, Otsubo H, Rutka JT, Snead III OC, Weiss SK, Smith ML. Intrahemispheric reorganization of language in children with medically intractable epilepsy of the left hemisphere. Journal of the International Neurological Society. 2007;13:505-516.
Kadis DS, Stollstorff M, Elliott I, Lach L, Smith ML. Cognitive and psychological predictors of everyday memory in children with intractable epilepsy. Epilepsy and Behavior. 2004;5:37-43.
Kadis DS. Shock treatment for suicidal, depressed, psychotic and schizophrenic patients. In G. Allen & Science 2000 Collective (Eds.), Communicating science – a collection by new writers (2nd ed.). Toronto: Life Rattle Press. 2004.
Darcy A. Krueger, MD, PhD Director, Tuberous Sclerosis Clinic
uses a combination of clinical investigation, basic science research and innovative social programs to improve clinical care for patients with tuberous sclerosis complex (TSC). We are active in human clinical trials with mTOR inhibitors to treat subependymal giant cell astrocytoma (SEGA), epilepsy and cognitive disabilities that occur in patients with TSC. In the laboratory, we are focused on understanding the mechanisms through which mTOR dysregulation in the brain contributes to TSC disease pathogenesis and developing suitable biomarkers capable of predicting disease severity and treatment response.
Director, Tuberous Sclerosis Clinic
Tuberous sclerosis; general neurology
Greiner H, Leach JL, Lee KH, Krueger DA. Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome. Seizure. 2011 Apr;20(3):266-70. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11.
Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10(5):299-313.
Diego A. Morita, MD Co-Director, New Onset Seizure Clinic
Co-Director, New Onset Seizure Clinic
Epilepsy; therapeutic drug management; pharmacogenetics
Dr. Morita obtained his medical degree with honors from the University of Buenos Aires School of Medicine in Buenos Aires, Argentina. He finished a three-year residency in Pediatrics at Buenos Aires British Hospital in Buenos Aires, Argentina. In 1996, he came to the United States and continued his training in pediatrics at Miami Children's Hospital in Miami, Florida.
Dr. Morita was then a resident in neurology at the University of Cincinnati, and later a fellow in child neurology at Cincinnati Children's. He completed fellowship training in clinical neurophysiology and epilepsy, and epilepsy clinical neuropharmacology, both at Cincinnati Children's.
After his fellowships, Dr. Morita opened a child neurology private practice in Buenos Aires, Argentina, and in 2005 returned and joined the faculty at Cincinnati Children's.
Dr. Morita's interests currently include the objective assessment of antiepileptic drug side effects, pharmacogenetics of antiepileptic drugs, and individualization of drug therapy.
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2011 Feb;52(2):370-6. doi: 10.1111/j.1528-1167.2010.02789.x.
Modi AC, Morita DA, Glauser TA. One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur. Pediatrics. 2008 Apr;121(4):e961-6.
Hope L. O'Brien, MD Director, Young Adult Headache Program, Division of Neurology
is an adult neurologist, interested in the transition stages of chronic headache as one develops from childhood into adults, with focus on the unique aspects of headaches and its impact on late adolescents and young adults. This includes identifying modifiable features in children with migraine that will result in reduction of intractable cases as one develops.
Director, Young Adult Headache Program, Division of Neurology
Director, Headache Medicine Fellowship
Ernest Pedapati, MD, MS, FAAP
is the director of the Cincinnati Children's Interventional Psychiatry Research Laboratory which is a non-surgical brain stimulation research program investigating childhood neurodevelopmental and psychiatric disorders. This laboratory represents an expansion of the well-established child neurology Gilbert TMS lab.
UC Department of Psychiatry and Behavioral Neuroscience
Neurodevelopmental disorders; autism spectrum disorders; fragile X; genetic disorders; schizophrenia
Dr. Pedapati specializes in the treatment of neuropsychiatric disease associated with ASD, genetic and other neurodevelopmental disorders including interdisciplinary treatment planning and advanced medication management. Prior to his faculty appointment, he had clinical and research training under Craig Erickson, MD, and pediatric transcranial magnetic stimulation under Donald Gilbert, MD, MS.
In 2013, the PI was successful in designing and obtaining IRB approval and competitive funding for a TMS project through the American Academy of Child & Adolescent Psychiatry Pilot Research Award and currently completing the study, "Cortical Plasticity in Adolescent Depression" which attempts to use TMS to determine whether abnormal neuroplasticity can be quantified in adolescent depression.
In his final year of residency, he applied and secured a highly competitive institutional mentor career development award (Proctor Scholar) to support 90% time dedicated to independent research activities including obtaining preliminary data on TMS measures of cortical plasticity in ASD and the development of an implicit false belief task of social cognition for future TMS modulation. In addition he continues to be an active Subinvestigator extensively contributing to NIH R01 project examining TMS measures of motor physiology in ADHD pioneered the use of SICI as a biomarker in ADHD and measurement of cortical plasticity in healthy youth.
MD: University of Massachusetts, Worcester, MA, 2009.
Residency: Pediatrics/Adult Psychiatry/Child Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, American Board of Pediatrics.
Modulation of Right Temporoparietal junction with TMS of the Implicit False Belief task. Principal Investigator. Cincinnati Children’s Hospital Medical Center. Jul 2014 - Jul 2015.
Anomalous Motor Physiology in ADHD. Subinvestigator. National Institutes of Health/National Institute of Mental Health. Sep 2012 - Aug 2017. R01 MH095014.
Douglas F. Rose, MD Pediatric Epileptologist, Division of Neurology
is interested in clinical neurophysiology of normal and abnormal brain function across multiple neuropsychiatric disorders using multiple modalities, principally electroencephalography (EEG), magnetoencephalography (MEG) and functional magnetic resonance imaging (fMRI). The normal brain function includes developmental vision, hearing, touch perception, spontaneous motor movement, attention, memory, language and pain perception. The neuropsychiatric disorders include epilepsy, cerebral palsy, stroke, tic disorders, obsessive-compulsive disorder and traumatic brain injury.
Epilepsy; improvement of the quality of life for children with epilepsy; studies of brain and physiology to better understand brain function
Dr. Rose grew up in Cleveland, Ohio. He and his wife lived briefly in Fairborn and Dayton, Ohio when first married. Subsequently they moved to Washington, DC to study and work at the National Institutes of Health. They then moved to Albuquerque, New Mexico for several years to continue work and research, before moving to Memphis, Tennessee and then Cincinnati.
MD: Case Western Reserve University, Cleveland, Ohio, 1977.
Residency: Rainbow Babies and Childrens, Cleveland, Ohio, 1979.
Fellowship: University Hospitals, Cleveland, Ohio, 1982.
Instructor:, Department of Neurology, University Hospitals, Cleveland, Ohio, 1983.
Fellowship: Epilepsy, National Institutes of Health, Bethesda, Md., 1983-1984.
Fellowship: Neurophysiology, National Institutes of Health, Bethesda, Md., 1984-1985.
Medical Staff Fellow: Clinical Epilepsy Section, National Institutes of Health, 1983-1984.
Medical Staff Fellow: EEG Laboratory, National Institutes of Health, 1984-1986.
Medical Staff Fellow: Unit on Neurophysiology, National Institutes of Health, 1986-1987.
Senior Staff Fellow: Unit on Neurophysiology, National Institutes of Health, 1987-1989.
Associate Professor: Department of Neurology, University of New Mexico, Albuquerque, N.M., 1989-1992.
Director: Center for Magnetoencephalography, Albuquerque, N.M., 1989-1992.
Associate Professor: Department of Pediatrics, University of Tennessee, Memphis, Tenn. 1992-2000.
Associate Professor: Department of Neurology, University of Tennessee, Memphis, Tenn. 1992-2000.
Adjunct Associate Professor: Memphis Speech and Hearing Center, Department of Audiology, University of Memphis, Tenn., 1998-present.
Division Chief: Child Neurology, Department of Pediatrics, University of Tennessee, 1994-2000.
Medical Director: Comprehensive Epilepsy Center, Le Bonheur Children's Medical, Center, Memphis, Tenn., 1992-2000.
Director: Cincinnati Children's Neurodiagnostic Laboratory, 2003 to present.
Director: Cincinnati Children's Clinical Neurophysiology Fellowship Program, 2001 to present.
Medical Director: Cincinnati Children's MEG Center, 2005 to present.
Certification: Pediatrics 1984 ; Neurology with special competence in Child Neurology 1984; Clinical Neurophysiology 1986; Added Qualifications in Clinical Neurophysiology, 1994.
Practice Locations: Cincinnati Children's Hospital Medical Center Main Campus; Outpatient Services -- Anderson.
Mark Schapiro, MD Fetal and Neonatal Neurologist, Division of Neurology
is interested in identifying specific biomarkers for future neurological deficits, which may also serve as therapeutic targets in neonatal care. For example, premature newborns are at high risk for later neurological disorders due to disruption of normal brain development by prematurity, in association with ischemic and inflammatory injury in utero or in the perinatal period.
Fetal and Neonatal Neurologist, Division of Neurology
Genetic and hormonal determinants of brain function; aging of the nervous system in developmental disorders
MD: University of Tennessee, Memphis, Tenn. 1976.
Residency: Pediatric Neurology, Boston City Hospital, Boston, Mass., 1980-1983.
Fellowship: National Institute on Aging, 1983-1989.
Certification: Pediatrics, 1985; Neurology and Psychiatry.
Brian J. Siroky, PhD
focuses on understanding the mechanisms of renal cyst and tumor formation that occur in tuberous sclerosis complex (TSC), and identification of targeted therapies for these lesions. Structural and functional relationships between renal epithelial primary cilia (specialized cellular organelles whose dysfunction is linked to cystogenesis) and mTOR signaling, the pathway that is dysregulated in TSC is also an area of interest.
Instructor, UC Department of Pediatrics
Tuberous sclerosis complex; polycystic kidney disease; primary cilia
BS: Western Kentucky University, Bowling Green, KY, 1999.
PhD: University of Alabama at Birmingham, Birmingham, AL, 2006.
Postdoctoral Fellowship: Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2006–2010.
Matthew R. Skelton, PhD
BA: Biology, Bellarmine University, Louisville, KY, 2000.
PhD: Molecular and Developmental Biology, University of Cincinnati, Cincinnati, OH, 2006.
Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Amos-Kroohs R, Williams MT. Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse. 2011 May;65(5):368-78. Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55.
Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. PLoS One. 2011 Jan 13;6(1):e16187.
Braun AA, Skelton MR, Vorhees CV, Williams MT. Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav. 2011 Jan;97(3):406-15.
Grace CE, Schaefer TL, Graham DL, Skelton MR, Williams MT, Vorhees CV. Effects of inhibiting neonatal methamphetamine-induced corticosterone release in rats by adrenal autotransplantation on later learning, memory, and plasma corticosterone levels. Int J Dev Neurosci. 2010 Jun;28(4):331-42. Grace CE, Schaefer TL, Herring NR, Graham DL, Skelton MR, Gudelsky GA, Williams MT, Vorhees CV. Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice. Neurotoxicol Teratol. 2010 May-Jun;32(3):346-55. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, Kitatani K, Hannun YA, Witte DP, Xu YH, Grabowski GA. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010 Mar 15;19(6):1088-97. Sun Y, Ran H, Zamzow M, Kitatani K, Skelton MR, Williams MT, Vorhees CV, Witte DP, Hannun YA, Grabowski GA. Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet. 2010 Feb 15;19(4):634-47 Skelton MR, Schaefer TL, Herring NR, Grace CE, Vorhees CV, Williams MT. Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats. Psychopharmacology (Berl). 2009 Jun;204(2):287-97.
Vorhees CV, Skelton MR, Grace CE, Schaefer TL, Graham DL, Braun AA, Williams MT. Effects of (+)-methamphetamine on path integration and spatial learning, but not locomotor activity or acoustic startle, align with the stress hyporesponsive period in rats. Int J Dev Neurosci. 2009 May;27(3):289-98.
Shannon M. Standridge, MPH, DO
is interested in the specific field of pediatric neurology, focusing on cost effective analyses. She seeks to understand the significance of healthcare savings and the magnitude of improvement in quality of life over an expected lifetime in young children undergoing epilepsy surgery.
Fellowship: Neurophysiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2008; Neurology, Nationwide Children's Hospital, Columbus, OH, 2007.
Residency: Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2004.
MPH: The Ohio State University College of Public Health, Columbus, OH, 2008.
DO: Kansas City University of Medicine and Biosciences, Kansas City, MO, 2002.
BS: Biology, Lyon College, Batesville, AS, 1997.
Mary Sutton, MD Pediatric Neurologist, Division of Neurology
MD: University of Rochester School of Medicine and Dentistry, Rochester, NY, 1989.
Residency: Pediatrics, Children's Hospital, Boston, MA.
Fellowship: Neurology, Children's Hospital, Boston, MA.
Certification: Pediatrics, 1996; Neurology, 1996.
Cameron Thomas, MD, MS Fetal and Neonatal Neurologist, Division of Neurology
is interested in understanding the effects of early life events such as seizures, medical procedures and pain on the developing brain.
MD: University of Colorado Health Sciences Center, Denver, CO, 2005.
Residency: Child Neurology, Cincinnati Children’s Hospital, Cincinnati, OH.
Certification: Neurology with Special Qualification in Child Neurology, 2010.
MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH, 2013.
Jennifer J. Vannest, PhD Assistant Director, Pediatric Neuroimaging Research Consortium
is interested in the use of functional MRI and behavioral testing to examine how epilepsy and neurodevelopmental disorders affect language function and the brain circuitry that supports it. The goal of these studies is to provide better treatment and educational strategies for children with these disorders.
Assistant Director, Pediatric Neuroimaging Research Consortium
Cognitive neuroscience of language and memory (using functional MRI); cognitive effects of epilepsy and neurodevelopmental disorders
Neurological disorders and language impairments
Jennifer Vannest, PhD, completed her undergraduate education at the Ohio State University and continued there for her graduate work. Her PhD is in linguistics, and in addition, her graduate training included a number of courses in cognitive psychology, neuropsychology and speech and hearing sciences. As a postdoctoral fellow at University of Michigan and University of Rochester, Dr. Vannest was trained to use functional MRI to study the brain mechanisms underlying language skill.
Dr. Vannest came to Cincinnati Children's Hospital Medical Center in 2006, and her current research makes use of functional MRI to examine how epilepsy and neurodevelopmental disorders affect language function, ultimately leading to better treatment and educational strategies for children with these disorders.
PhD: Ohio State University, Linguistics.
Postdoctoral Training: University of Michigan (Psychology), University of Rochester (Brain and Cognitive Sciences).
Vannest J, Newport EL, Newman AJ, Bavelier D. Interplay between morphology and frequency in lexical access: The case of the base frequency effect. Brain Res. 2011 Feb 10;1373:144-59. Korostenskaja M, Pardos M, Fujiwara H, Kujala T, Horn P, Rose D, Byars A, Brown D, Seo JH, Wang Y, Vannest J, Xiang J, Degrauw T, Näätänen R, Lee KH. Neuromagnetic evidence of impaired cortical auditory processing in pediatric intractable epilepsy. Epilepsy Res. 2010 Nov;92(1):63-73.
Vannest J, Rasmussen J, Eaton KP, Patel K, Schmithorst V, Karunanayaka P, Plante E, Byars A, Holland S. FMRI activation in language areas correlates with verb generation performance in children. Neuropediatrics. 2010 Oct;41(5):235-9. Szaflarski JP, Eaton K, Ball AL, Banks C, Vannest J, Allendorfer JB, Page S, Holland SK. Poststroke Aphasia Recovery Assessed With Functional Magnetic Resonance Imaging and a Picture Identification Task. J Stroke Cerebrovasc Dis. 2010 Aug 17. Karunanayaka P, Schmithorst VJ, Vannest J, Szaflarski JP, Plante E, Holland SK. A group independent component analysis of covert verb generation in children: a functional magnetic resonance imaging study. NeuroImage. 2010 May 15;51(1):472-87. Vannest J, Karunanayaka PR, Schmithorst VJ, Szaflarski JP, Holland SK. Language networks in children: evidence from functional MRI studies. AJR Am J Roentgenol. 2009 May;192(5):1190-6. Vannest JJ, Karunanayaka PR, Altaye M, Schmithorst VJ, Plante EM, Eaton KJ, Rasmussen JM, Holland SK. Comparison of fMRI data from passive listening and active-response story processing tasks in children. J Magn Reson Imaging. 2009 Apr;29(4):971-6. Wang Y, Xiang J, Kotecha R, Vannest J, Liu Y, Rose D, Schapiro M, Degrauw T. Spatial and frequency differences of neuromagnetic activities between the perception of open- and closed-class words. Brain Topogr. 2008 Dec;21(2):75-85.
Liu Y, Xiang J, Wang Y, Vannest JJ, Byars AW, Rose DF. Spatial and frequency differences of neuromagnetic activities in processing concrete and abstract words. Brain Topogr. 2008 Spring;20(3):123-9.
Vannest J, Szaflarski JP, Privitera MD, Schefft BK, Holland SK. Medial temporal fMRI activation reflects memory lateralization and memory performance in patients with epilepsy. Epilepsy Behav. 2008 Apr;12(3):410-8.
Charles V. Vorhees, PhD
Principal areas of investigation are how drugs, genetic mutations, environmental agents, and stressors affect prenatal and neonatal brain development and behavior. The lab is particularly interested in the long-term effects of such perturbations on cognitive development.
Visit the Vorhees-Williams Lab.
Dr. Vorhees came to Cincinnati Children’s in 1976 as a postdoctoral research scholar and was recruited to the faculty in 1978 as assistant professor. He was promoted to associate professor in 1982, tenured in 1984, and promoted to professor in 1988 with primary appointment in pediatrics and joint appointment in environmental health. He is co-director of the Animal Behavior Core and program director of the Teratology Training Program. He is on the graduate faculty of the Graduate Programs in Neuroscience (NS) and Molecular and Developmental Biology (MDB). He is section editor of the journal Neurotoxicology and Teratology and served as editor-in-chief for nine years. He was director of the MDB Graduate Program for six years and served in other leadership positions for 15 years. Dr. Vorhees has also served in leadership positions in the NS Program and is currently a member of the Admissions Committee. Dr. Vorhees has been extramurally funded for 35 years, receiving grants from NIH, NSF, FDA and other agencies. He holds an NIH T32 training grant funded for years 36-40 through 2017. He is a founding member of the Neurobehavioral Teratology Society in 1977 and was elected president in 1984-85 and 2012-13. He is an elected member of Sigma Xi, an Eli Lilly Distinguished Lecturer in 1990, and a Society for Neuroscience Grass Foundation Lecturer in 2002. Dr. Vorhees has served on multiple FDA, NRC, and EPA advisory panels. He has been an NIH grant reviewer on varies committees for more than 26 years. He has also reviewed grants for NSF, VA, EPA; March of Dimes, and other agencies and foundations in the U.S.; and for funding agencies in Israel, Ireland, Great Britain, and New Zealand. His research focuses on brain development and behavior. As of 2013 he has published than more 276 journal articles and book chapters.
Visit the Vorhees Lab Site
Visit the Animal Behavioral Core Site
MA: Neurobiology Program, Vanderbilt University, Nashville, TN, 1973.
PhD: Neurobiology Program, Vanderbilt University, Nashville, TN, 1976.
Hautman ER, Williams MT, Vorhees CV, Skelton MR. Female mice heterozygous for creatine transporter deficiency show moderate cognitive deficits. J Inherited Metab Dis. 2014 Jan;37(1):63-8.
Sun Y, Zamzow M, Ran H, Zhang W, Quinn B, Barnes S, Witte DP, Setchell KDR, Williams MT, Vorhees CV, Grabowski GA. Tissue-specific effects of saposin A and saposin B on glycosphingolipids degradation in mutant mice. Hum Mol Genet. 2013 Jun 15;22(12):2435-50.
Amos-Kroohs RM, Williams MT, Braun AA, Graham DL, Webb CL, Birtles TS, Greene RM, Vorhees CV, Pisano MM. Neurobehavioral phenotype of C57BL/6J mice prenatally and neonatally exposed to cigarette smoke. Neurotoxicol Teratol. 2013;35, 34-45.
Schaefer TL, Grace CE, Braun AA, Amos-Kroohs RM, Graham DL, Skelton MR, Williams MT, Vorhees CV. Cognitive impairments from developmental exposure to serotonergic drugs: citalopram or MDMA. Int J Neuropsychopharmacol. 2013;16, 1383-94.
Graham DL, Amos-Kroohs RM, Braun AA, Grace CE, Schaefer TL, Skelton MR, Vorhees CV, Williams MT. Neonatal (+)-methamphetamine exposure in rats alters adult locomotor responses to dopamine D1 and D2 agonists and to a glutamate NMDA receptor antagonist, but not to serotonin agonists. Int J Neuropsychopharmacol. 2012;16, 377-391.
Vorhees CV, Graham DL, Braun AA, Schaefer TL, Skelton MR, Richtand NM, Williams MT. Prenatal immune challenge in rats: Altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to Poly IC. Synapse. 2012;66(8), 725-737.
Schaefer TL, Braun AA, Amos-Kroohs RM, Williams MT, Ostertag E, Vorhees CV. A new model of Pde4d deficiency: Genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects. Genes Brain Behav. 2012;11(5), 614-622.
Chen Y, Curran CP, Nebert DW, Patel KV, Williams MT, Vorhees CV. Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm(-/-) knockout mice. Neurotoxicol Teratol. 2012;34, 450-457.
Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Burns LA, Amos-Kroohs RM, Williams MT, Vorhees CV. Distinct periods of developmental sensitive to the effects 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats. Int J Neuropsychopharmacol. 2012;15, 811-824.
Braun AA, Graham DL, Schaefer TL, Vorhees CV, Williams MT. Dorsal striatal dopamine depletion impairs both allocentric and egocentric navigation in rats. Neurobiol Learn Mem. 2012;97(4), 402-408.
Prenatal SSRI Exposure and ASD. Principal Investigator. Congressionally Directed Medical Research Program, Department of Defense. 2013-2015.
Latrophilin-3 and ADHD: A new potential mechanism. Principal Investigator. National Institutes of Health. 2013-2015.
Acute neurotoxicity of pyrethroids. Co-Principle Investigator. CAPHRA (Council for the Advancement of Pyrethroid Human Risk Assessment). 2012-2015.
Transgenerational inheritance of epigenetic effects of polychlorinated biphenyls. Co-Principal Investigator. National Institutes of Health. 2013-2016.
Training Grant in Teratology. Principal Investigator. National Institutes of Health. 2012-2017.
Kris R. Wesselkamper, MD Pediatric Neurologist, Division of Neurology
is interested in including quality improvement, safety and standardization of care for patients with neurologic conditions who are admitted to the hospital.
MD: University of Cincinnati, Cincinnati, OH, 2000.
Pediatric Residency: MetroHealth Medical Center, Cleveland, OH, 2000-2003.
Child Neurology Residency: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2003-2006.
Board Certification: Neurology with Special Qualification in Child Neurology, American Board of Psychiatry and Neurology, 2007.
Michael T. Williams, PhD
Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine Transporter (CrT; Slc6a8) Knockout Mice as a Model of Human CrT Deficiency. PLoS One. 2011 Jan 13;6(1):e16187. Curran CP, Vorhees CV, Williams MT, Genter MB, Miller ML, Nebert DW. In utero and lactational exposure to a complex mixture of polychlorinated biphenyls: toxicity in pups dependent on the Cyp1a2 and Ahr genotypes. Toxicol Sci. 2011 Jan;119(1):189-208. Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55. Braun AA, Skelton MR, Vorhees CV, Williams MT. Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav. 2011 Jan;97(3):406-15.
Schaefer TL, Grace CE, Gudelsky GA, Vorhees CV, Williams MT. Effects on plasma corticosterone levels and brain serotonin from interference with methamphetamine-induced corticosterone release in neonatal rats. Stress. 2010 Nov;13(6):469-80. Herring NR, Gudelsky GA, Vorhees CV, Williams MT.(+)-Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse. 2010 Oct;64(10):773-85.
Schaefer TL, Lingrel JB, Moseley AE, Vorhees CV, Williams MT. Targeted mutations in the Na,K-ATPase alpha 2 isoform confer ouabain resistance and result in abnormal behavior in mice. Synapse. 2010 Oct 8.
Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Amos-Kroohs R, Williams MT. Comparison of (+)-methamphetamine, ±-Methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse. 2010 Aug 20.
Grace CE, Schaefer TL, Graham DL, Skelton MR, Williams MT, Vorhees CV. Effects of inhibiting neonatal methamphetamine-induced corticosterone release in rats by adrenal autotransplantation on later learning, memory, and plasma corticosterone levels. Int J Dev Neurosci. 2010 Jun;28(4):331-42. Zhu H, Mingler MK, McBride ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Williams MT, Vorhees CV, Rothenberg ME. Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology. 2010 Sep;35(8):1119-32.
Brenda Wong, MD, MBBS Director, Comprehensive Neuromuscular Center/MDA Clinic
focuses on neuromuscular disorders in children including clinical research in Duchenne muscular dystrophy and spinal muscular atrophy and genomics in DMD and NM disorders.
Director, Comprehensive Neuromuscular Center/MDA Clinic
UC Department of Neurology
After medical school, Brenda Wong, MD, received training in general pediatrics and worked as a pediatrician for a few years before doing her three-year child neurology fellowship at Cincinnati Children's Hospital Medical Center.
Dr. Wong also received training in pediatric neuromuscular disorders at Hammersmith Hospital, London with Dr. Victor Dubowitz and Dr. Francesco Muntoni. Dr. Wong's training in EMGs was accomplished with Dr. John Quinlan in the Department of Neurology at University of Cincinnati.
Post fellowship training, Dr. Wong was practicing child neurology in private practice prior to joining Cincinnati Children's in 1999.
Besides general neurology patients, Dr. Wong sees patients with neuromuscular disorders in the Neuromuscular Clinic and provide diagnostic services like EMGs and evaluation for muscle biopsies. Comprehensive management is supported by the Division of Rehabilitative Medicine, Pulmonary Medicine, Pediatric Orthopedics and the Muscular Dystrophy Association.
MD: University of Singapore, 1980.
Residency: University Department of Pediatrics, Singapore, 1981, 1984-85; Royal Hospital for Sick Children, Edinburgh, 1985-88.
Fellowship: Child Neurology, Children's Hospital Medical Center, Cincinnati, OH, 1994-97; Neuromuscular Disorders, Hammersmith Hospital, London, 1997.
Certification: Child Neurology, 1998.
Miles MV, Putnam PE, Miles L, Tang PH, DeGrauw AJ, Wong BL, Horn PS, Foote HL, Rothenberg ME. Acquired coenzyme Q10 deficiency in children with recurrent food intolerance and allergies. Mitochondrion. 2011 Jan;11(1):127-35.
Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ. T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. Radiology. 2010 Jun;255(3):899-908. Kim HK, Laor T, Horn PS, Wong B. Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol. 2010 May-Jun;11(3):304-11. Yang Z, Funke BH, Cripe LH, Vick GW 3rd, Mancini-Dinardo D, Peña LS, Kanter RJ, Wong B, Westerfield BH, Varela JJ, Fan Y, Towbin JA, Vatta M. LAMP2 microdeletions in patients with Danon disease. Circ Cardiovasc Genet. 2010 Apr;3(2):129-37. Henderson RC, Berglund LM, May R, Zemel BS, Grossberg RI, Johnson J, Plotkin H, Stevenson RD, Szalay E, Wong B, Kecskemethy HH, Harcke HT. The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Miner Res. 2010 Mar; 25(3):520-6.
Steve W. Wu, MD Pediatric Neurologist, Division of Neurology
Pediatric neurology with specialty in Pediatric Movement Disorder; botulinum toxin (Botox) injection for dystonia, spasticity, tics; deep brain stimulation (DBS)
Dr. Steve Wu is a pediatric neurologist with interests in children with movement disorders. Drs. Wu, Gilbert (Neurology) and Vadivelu (Neurosurgery) also work together in the Dystonia/Deep Brain Stimulation Clinic to care for children/adolescents with dystonia and complex movement disorders.
Dr. Wu’s research interest focuses on movement disorders and neuroplasticity of the brain. Dr. Wu collaborates with Dr. Donald Gilbert in the Transcranial Magnetic Stimulation Lab at Cincinnati Children’s Hospital Medical Center.
Wu SW, Gilbert DL. Measuring neuroplasticity in children using brain stimulation (Commentary). Dev Med Child Neurol. 2015.
Hong YH, Wu SW, Pedapati EV, Horn PS, Huddleston DA, Laue CS, Gilbert DL. Safety and Tolerability of Theta Burst Stimulation versus Single and Paired Pulse Transcranial Magnetic Stimulation: A Comparative Study of 165 Pediatric Subjects. Front Hum Neurosci. 2015.
Burrow TA, Sun Y, Prada CE, Bailey L, Zhang W, Brewer A, Wu SW, Setchell K, Witte D, Cohen MB, Grabowski GA. CNS, Lung, and Lymph Node involvement in Gaucher disease type 3 after 11 years therapy: Clinical, Histopathologic, and Biochemical Findings. Mol Genet Metab. 2014.
Chen TH, Wu SW, Dixon S, Shahana N, Huddleston DA, Sarvis AR, Sallee FR, Gilbert DL. Reduced short interval cortical inhibition correlates with atomoxetine response in children with attention-deficit hyperactivity disorder (ADHD). J Child Neurol. 2014;29:1672-9.
Wu SW, Maloney T, Gilbert DL, Dixon SG, Horn PS, Huddleston DA, Eaton K, Vannest J. Functional MRI-navigated Repetitive Transcranial Magnetic Stimulation over Supplementary Motor Area in Chronic Tic Disorders. Brain Stimulation. 2014;7(2):212–218.
Hedera P, Xiao J, Puschmann A, Momčilović D, Wu SW, LeDoux MS. Novel PRRT2 mutation in an African-American family with paroxysmal kinesigenic dyskinesia. BMC Neurology. 2012;12:93.
Klotz J, Johnson M, Wu SW, Isaacs KM, Gilbert DL. Relationship between Reaction Time Variability and Motor Skill Development in ADHD. Child Neuropsychology. 2012;18:576-585.
Wu SW, Gilbert DL, Shahana N, Huddleston DA, Mostofsky SH. Transcranial Magnetic Stimulation Measures in Attention-Deficit/Hyperactivity Disorder. Pediatric Neurology. 2012;47:177-185.
Wu SW, Shahana N, Huddleston DA, Gilbert DL. Effects of 30 Hz Theta Burst Transcranial Magnetic Stimulation on the Primary Motor Cortex. Journal of Neuroscience Methods. 2012;208:161-164.
Wu SW, Shahana N, Huddleston DA, Lewis AN, Gilbert DL. Safety and Tolerability of Theta-Burst Transcranial Magnetic Stimulation in Children. Developmental Medicine and Child Neurology. 2012;54:636-639.
Jing Xiang, MD, PhD Director of MEG Research, Division of Neurology
Director of MEG Research, Division of Neurology
Epilepsy and pre-operative functional mapping
Visit the Xiang Lab.
MD: Postgraduate Medical School, Beijing, China, 1994.
PhD: The Graduate University for Advanced Studies, Okazaki, Japan, 1998.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center